Published on 28 Dec 2023 on Zacks via Yahoo Finance
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
Shares of Coherus BioSciences, Inc. CHRS were up 23.4% on Dec 27 after the company announced that the FDA has approved Udenyca Onbody, the on-body injector presentation of Udenyca (pegfilgrastim-cbqv).
Udenyca is a biosimilar of Amgen’s AMGN Neulasta.
Amgen’s Neulasta is indicated for use in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment.